Accessibility Menu
 
Achieve Life Sciences logo

Achieve Life Sciences

(NASDAQ) ACHV

Current Price$2.66
Market Cap$141.09M
Since IPO (2017)-100%
5 Year-78%
1 Year-9%
1 Month-43%

Achieve Life Sciences Financials at a Glance

Market Cap

$141.09M

Revenue (TTM)

$0.00

Net Income (TTM)

$54.65M

EPS (TTM)

$-1.29

P/E Ratio

-2.05

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$2.66

Volume

41,361

Open

$2.82

Previous Close

$2.66

Daily Range

$2.64 - $2.83

52-Week Range

$1.84 - $6.03

ACHV News

ACHV: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Achieve Life Sciences

Industry

Biotechnology

Employees

28

CEO

Richard Alistair Balfour Stewart

Headquarters

Vancouver, BC V6E 4H1, CA

ACHV Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-258%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-48.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$141.09M

Shares Outstanding

53.24M

Volume

41.36K

Short Interest

0.00%

Avg. Volume

696.81K

Financials (TTM)

Gross Profit

$228.00K

Operating Income

$54.88M

EBITDA

$54.65M

Operating Cash Flow

$49.47M

Capital Expenditure

$3.00K

Free Cash Flow

$49.47M

Cash & ST Invst.

$36.40M

Total Debt

$14.96M

Achieve Life Sciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$57.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$141.09M

N/A

Market Cap/Employee

$5.64M

N/A

Employees

25

N/A

Net Income

$14.66M

-18.6%

EBITDA

$14.67M

-21.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$21.45M

-12.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$11.19M

+13.0%

Short Term Debt

$3.77M

+6745.5%

Return on Assets

-1.31%

N/A

Return on Invested Capital

-1.68%

N/A

Free Cash Flow

$17.98M

-95.7%

Operating Cash Flow

$17.98M

-95.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SGMTSagimet Biosciences Inc.
$4.89-4.31%
HUMAHumacyte, Inc.
$0.68-13.21%
IMRXImmuneering Corporation
$4.96-4.98%
ARCTArcturus Therapeutics Holdings Inc.
$6.76-4.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About ACHV

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.